scispace - formally typeset
T

Tom Jacks

Researcher at Merck & Co.

Publications -  14
Citations -  934

Tom Jacks is an academic researcher from Merck & Co.. The author has contributed to research in topics: Growth hormone secretagogue & Growth hormone secretion. The author has an hindex of 12, co-authored 14 publications receiving 915 citations.

Papers
More filters
Journal ArticleDOI

A nonpeptidyl growth hormone secretagogue

TL;DR: The mechanism of action of L-692,429 and studies with peptidyl and nonpeptidyl antagonists suggest that this molecule is a mimic of the growth hormone-releasing hexapeptide His-D-Trp-Ala-Tr phe-Phe-Lys-NH2 (GHRP-6).
Journal Article

Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland.

TL;DR: A GH secretagogue MK0677, is described, which synergizes with growth hormone releasing hormone (GHRH) through a receptor and signal transduction pathway distinct from that of GHRH and is a functional antagonist of somatostatin (SRIF).
Journal ArticleDOI

Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles

TL;DR: When L-692,585 was administered once daily for 14 consecutive days at 0, 0.01 or 0.10 mg/kg to each of 6 dogs, peak plasma GH levels and total GH release on days 1, 8 and 15 significantly increased in a dose-dependent manner, and no desensitization was evident.
Journal ArticleDOI

Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.

TL;DR: It is demonstrated that L-692,429 is a novel nonpeptidyl secretagogue that stimulates a marked, but transient, increase in serum GH levels in the dog.
Journal ArticleDOI

Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles

TL;DR: Chronic oral administration of MK-0677 was associated with significant increases in GH and IGF-I levels that were maintained for the duration of the treatment, suggesting that IGF-i mediated negative feedback on both the GH and cortisol axes prevents hyperstimulation of the GH axis by MK- 0677.